Pfizer succeeds COVID-19 vaccine safety milestone
Pfizer prepares to file its COVID-19 vaccine for emergency use authorization (EUA) after succeeding a key safety breakthrough. Pfizer now has the median two-month follow-up data needed for securing EUA from the FDA, moving a step closer for bringing its vaccine to market in the United States, as said by CEO Albert Bourla, PhD.
Speaking about the virtual events that were hosted by The New York Times and Stat, Bourla said Pfizer is preparing to try EUA for the vaccine that it developed with BioNTech, using the safety data and the efficacy results it provided a glimpse of last week. It is not known when Pfizer...
